Rocketman, all you say may be true but that doesn't change the FACT that the Third Eye Loan documents states the following. You can read it in the most recent MD&A yourself or see the copy and paste below (bolding added):

"In May 2018, we obtained a US$30 million senior secured term loan from Third Eye Capital Corporation, as agent for a syndicate of lenders. The loan bears interest at a rate of 10% per annum, payable monthly, and has a maturity date of May 4, 2019. The loan is secured by all of our assets and contains certain restrictive financial covenants, covenants relating to the completion of the BETonMACE clinical trial (top line data on or before January 31, 2019) and other customary covenants."